Chemotherapy and radiotherapy can not only reduce the heavy tumor burden of SCLC and further reinvigorate immune function but can also elevate PD-L1 expression and tumor antigen presentation by MHC molecules, thus favoring subsequent immunotherapy [106, 107]. Here, HLA-C is linked to neoplasm.